Dr Kate Smith

Currently Senior Medicinal Chemist in the Cancer Research UK Manchester Institute Drug Discovery Unit, I lead the chemistry on our poly(ADP ribose) glycohydrolase, PARG project, focusing on the development of small molecule inhibitors of this DNA damage repair enzyme. PARG inhibitors have the potential to decrease the repair of DNA single strand breaks, leading to cell death and ultimately delivering novel and clinically relevant therapeutic agents.
Previously I studied my undergraduate and PhD degrees at Durham University in synthetic organic chemistry, my thesis titled ‘Synthesis and Reactions of New N-Heteroaryl Boronic Acids’. Following this I undertook a Research Associate position at the Newcastle Cancer Centre, Newcastle University where I worked on the development of small molecule inhibitors of DNA-dependent protein kinase (DNA-PK), as potential cancer therapeutics, this project was conducted in collaboration with AstraZeneca.